PD-1 Inhibitors Combined with Tyrosine Kinase Inhibitors with or without Hepatic Artery Infusion Chemotherapy for the First-Line Treatment of HBV-Related Advanced Hepatocellular Carcinoma: A Retrospective Study

References

• Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Venook AP, Papandreou C, Furuse J, de Guevara LL. The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist. 2010;15(4):5–13. doi:10.1634/theoncologist.2010-S4-05
   PubMedGoogle Scholar
• Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7(1):6. doi:10.1038/s41572-020-00240-3
   PubMed Web of Science ®Google Scholar
• Zhou Y, Li X, Long G, Tao Y, Zhou L, Tang J. Identification and validation of a tyrosine metabolism-related prognostic prediction model and characterization of the tumor microenvironment infiltration in hepatocellular carcinoma. Front Immunol. 2022;13:994259. doi:10.3389/fimmu.2022.994259
   PubMedGoogle Scholar
• Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. Engl J Med. 2008;359(4):378–390. doi:10.1056/NEJMoa0708857
   PubMed Web of Science ®Google Scholar
• Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a Phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25–34. doi:10.1016/S1470-2045(08)70285-7
   PubMed Web of Science ®Google Scholar
• Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised Phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163–1173. doi:10.1016/S0140-6736(18)30207-1
   PubMed Web of Science ®Google Scholar
• Choi NR, Kim JY, Hong JH, et al. Comparison of the outcomes between sorafenib and lenvatinib as the first-line systemic treatment for HBV-associated hepatocellular carcinoma: a propensity score matching analysis. BMC Gastroenterol. 2022;22(1):135. doi:10.1186/s12876-022-02210-3
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Chan SL, Furuse J, Galle PR, Sangro B. A randomized, multicenter phase 3 study of durvalumab (d) and tremelimumab (t) as first-line treatment in patients with unresectable hepatocellular carcinoma (HCC): himalaya study. J clin oncol. 2018;36(15_suppl):TPS4144–TPS4144. doi:10.1200/JCO.2018.36.15_suppl.TPS4144
   Web of Science ®Google Scholar
• Yau T, Park JW, Finn RS, et al. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2022;23(1):77–90. doi:10.1016/S1470-2045(21)00604-5
   PubMed Web of Science ®Google Scholar
• Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. Engl J Med. 2020;382(20):1894–1905. doi:10.1056/NEJMoa1915745
   PubMed Web of Science ®Google Scholar
• Ren Z, Xu J, Bai Y, et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, Phase 2-3 study [published correction appears in Lancet Oncol. Lancet Oncol. 2021;22(7):977–990. doi:10.1016/S1470-2045(21)00252-7
   PubMed Web of Science ®Google Scholar
• Bartkowski R, Berger MR, Aguiar JL, et al. Experiments on the efficacy and toxicity of locoregional chemotherapy of liver tumors with 5-fluoro-2’-deoxyuridine (FUDR) and 5-fluorouracil (5-FU) in an animal model. J Canc Res Clin Oncol. 1986;111(1):42–46. doi:10.1007/BF00402774
   PubMed Web of Science ®Google Scholar
• Liu BJ, Gao S, Zhu X, et al. Real-world study of hepatic artery infusion chemotherapy combined with anti-PD-1 immunotherapy and tyrosine kinase inhibitors for advanced hepatocellular carcinoma. Immunotherapy. 2021;13(17):1395–1405. doi:10.2217/imt-2021-0192
   PubMed Web of Science ®Google Scholar
• Luo L, Xiao Y, Zhu G, et al. Hepatic arterial infusion chemotherapy combined with PD-1 inhibitors and tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: a tertiary medical center experience. Front Oncol. 2022;12:1004652. doi:10.3389/fonc.2022.1004652
   PubMed Web of Science ®Google Scholar
• Mei J, YH T, Wei W, et al. Hepatic arterial infusion chemotherapy combined with PD-1 Inhibitors Plus Lenvatinib Versus PD-1 Inhibitors Plus Lenvatinib for Advanced Hepatocellular Carcinoma. Front Oncol. 2021;11:618206. doi:10.3389/fonc.2021.618206
   PubMed Web of Science ®Google Scholar
• Lai Z, He M, Bu X, et al. Lenvatinib, toripalimab plus hepatic arterial infusion chemotherapy in patients with high-risk advanced hepatocellular carcinoma: a biomolecular exploratory, Phase II trial. Eur J Cancer. 2022;174:68–77. doi:10.1016/j.ejca.2022.07.005
   PubMed Web of Science ®Google Scholar
• Zhang TQ, Geng ZJ, Zuo MX, et al. Camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and hepatic artery infusion chemotherapy for hepatocellular carcinoma in Barcelona Clinic Liver Cancer stage C (TRIPLET): a phase II study. Signal Transt Target Ther. 2023;8(1):413. doi:10.1038/s41392-023-01663-6
   PubMed Web of Science ®Google Scholar
• Fu Y, Peng W, Zhang W, et al. Induction therapy with hepatic arterial infusion chemotherapy enhances the efficacy of lenvatinib and pd1 inhibitors in treating hepatocellular carcinoma patients with portal vein tumor thrombosis. J Gastroenterol. 2023;58(4):413–424. doi:10.1007/s00535-023-01976-x
   PubMed Web of Science ®Google Scholar
• Qi Q, Zhuang L, Shen Y, et al. A novel systemic inflammation response index (SIRI) for predicting the survival of patients with pancreatic cancer after chemotherapy. Cancer. 2016;122(14):2158–2167. doi:10.1002/cncr.30057
   PubMed Web of Science ®Google Scholar
• Zhang Y, Xing Z, Zhou K, Jiang S. The predictive role of systemic inflammation response index (siri) in the prognosis of stroke patients. Clin Interv Aging. 2021;16:1997–2007. doi:10.2147/CIA.S339221
   PubMed Web of Science ®Google Scholar
• Xie QK, Chen P, Hu WM, et al. The systemic immune-inflammation index is an independent predictor of survival for metastatic colorectal cancer and its association with the lymphocytic response to the tumor. J Transl Med. 2018;16(1):273. doi:10.1186/s12967-018-1638-9
   PubMed Web of Science ®Google Scholar
• Geng Y, Zhu D, Wu C, et al. A novel systemic inflammation response index (SIRI) for predicting postoperative survival of patients with esophageal squamous cell carcinoma. Int Immunophar. 2018;65:503–510. doi:10.1016/j.intimp.2018.10.002
   PubMed Web of Science ®Google Scholar
• Li S, Lan X, Gao H, et al. Systemic Inflammation Response Index (SIRI), cancer stem cells and survival of localised gastric adenocarcinoma after curative resection. Cancer Res Clin Oncol. 2017;143(12):2455–2468. doi:10.1007/s00432-017-2506-3
   PubMed Web of Science ®Google Scholar
• Zhu M, Chen L, Kong X, et al. The systemic inflammation response index as an independent predictor of survival in breast cancer patients: A retrospective study. Front Mol Biosci. 2022;9:856064. doi:10.3389/fmolb.2022.856064
   PubMed Web of Science ®Google Scholar
• Zeng X, Liu G, Pan Y, Li Y. Development and validation of immune inflammation-based index for predicting the clinical outcome in patients with nasopharyngeal carcinoma. J Cell Mol Med. 2020;24(15):8326–8349. doi:10.1111/jcmm.15097
   PubMed Web of Science ®Google Scholar
• Saroul N, Puechmaille M, Lambert C, et al. Prognosis in head and neck cancer. Imp Nutrit Biological Inflam Status. 2022;166(1):118–127. doi:10.1177/01945998211004592
   Google Scholar
• Shan M, Deng Y, Zou W, et al. Salvage radiotherapy strategy and its prognostic significance for patients with locoregional recurrent cervical cancer after radical hysterectomy: a multicenter retrospective 10-year analysis. BMC Cancer. 2023;23(1):905. doi:10.1186/s12885-023-11406-z
   PubMed Web of Science ®Google Scholar
• Mao S, Yu X, Sun J, et al. Development of nomogram models of inflammatory markers based on clinical database to predict prognosis for hepatocellular carcinoma after surgical resection. BMC Cancer. 2022;22(1):249. doi:10.1186/s12885-022-09345-2
   PubMed Web of Science ®Google Scholar
• Zhao M, Duan X, Han X, et al. Sarcopenia and systemic inflammation response index predict response to systemic therapy for hepatocellular carcinoma and are associated with immune cells. Front Oncol. 2022;12:854096. doi:10.3389/fonc.2022.854096
   PubMed Web of Science ®Google Scholar
• Demirtas CO, D’Alessio A, Rimassa L, Sharma R, Pinato DJ. ALBI grade: evidence for an improved model for liver functional estimation in patients with hepatocellular carcinoma. JHEP Rep. 2021;3(5):100347. doi:10.1016/j.jhepr.2021.100347
   PubMedGoogle Scholar
• Peng Y, Wei Q, He Y, et al. ALBI versus child-pugh in predicting outcome of patients with HCC: a systematic review. Rev Gastroenterol Hepatol. 2020;14(5):383–400. doi:10.1080/17474124.2020.1748010
   PubMed Web of Science ®Google Scholar
• Kao WY, Su CW, Chiou YY, et al. Hepatocellular Carcinoma: Nomograms Based on the albumin-bilirubin grade to assess the outcomes of radiofrequency ablation. Radiology. 2017;285(2):670–680. doi:10.1148/radiol.2017162382
   PubMed Web of Science ®Google Scholar
• Nam JY, Choe AR, Sinn DH, et al. A differential risk assessment and decision model for Transarterial chemoembolization in hepatocellular carcinoma based on hepatic function. BMC Cancer. 2020;20(1):504. doi:10.1186/s12885-020-06975-2
   PubMed Web of Science ®Google Scholar
• Li MX, Zhao H, Bi XY, et al. Prognostic value of the albumin-bilirubin grade in patients with hepatocellular carcinoma: validation in a Chinese cohort. Hepatol Res. 2017;47(8):731–741. doi:10.1111/hepr.12796
   PubMed Web of Science ®Google Scholar
• Pinato DJ, Kaneko T, Saeed A, et al. Immunotherapy in hepatocellular cancer patients with mild to severe liver dysfunction: Adjunctive role of the albi grade. Cancer. 2020;12(7):1862. doi:10.3390/cancers12071862
   Google Scholar
• Tada T, Kumada T, Toyoda H, et al. Impact of albumin-bilirubin grade on survival in patients with hepatocellular carcinoma who received sorafenib: an analysis using time-dependent receiver operating characteristic. J Gastroenterol Hepatol. 2019;34(6):1066–1073. doi:10.1111/jgh.14564
   PubMed Web of Science ®Google Scholar
• Kudo M, Galle PR, Brandi G, et al. Effect of ramucirumab on ALBI grade in patients with advanced HCC: results from REACH and REACH-2. JHEP Rep. 2020;3(2):100215. doi:10.1016/j.jhepr.2020.100215
   PubMedGoogle Scholar
• Johnson PJ, Berhane S, Kagebayashi C, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-The ALBI grade. J Clin Oncol. 2015;33(6):550–558. doi:10.1200/JCO.2014.57.9151
   PubMed Web of Science ®Google Scholar
• Liu WM, Fowler DW, Smith P, Dalgleish AG. Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses. J Cancer. 2010;102(1):115–123. doi:10.1038/sj.bjc.6605465
   Web of Science ®Google Scholar
• Lake RA, Robinson BW. Immunotherapy and chemotherapy--a practical partnership. Rev Cancer. 2005;5(5):397–405. doi:10.1038/nrc1613
   PubMed Web of Science ®Google Scholar
• Kudo M. Scientific rationale for combined immunotherapy with PD-1/PD-L1 Antibodies and VEGF Inhibitors in advanced hepatocellular Carcinoma. Cancer. 2020;12(5):1089. doi:10.3390/cancers12051089
   Google Scholar
• Hegde PS, Wallin JJ, Mancao C. Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics. Semin Cancer Biol. 2018;52(Pt 2):117–124. doi:10.1016/j.semcancer.2017.12.002
   PubMed Web of Science ®Google Scholar
• Chung AS, Lee J, Ferrara N. Targeting the tumour vasculature: insights from physiological angiogenesis. Rev Cancer. 2010;10(7):505–514. doi:10.1038/nrc2868
   PubMed Web of Science ®Google Scholar